XML 112 R94.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2020
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]        
Income (loss) before income taxes $ (1,284) $ (624) $ (3,163)  
Statutory tax rate in Israel 23.00% 23.00% 23.00% 23.00%
Theoretical provision for income taxes $ (295) $ (144) $ (727)  
Increase (decrease) in the provision for income taxes due to:        
Tax benefits arising from net deferred taxes, resulting from intellectual property related integration plans, including carryforward losses (87) (272) 0  
The parent company and its israeli subsidiaries - settlement with the israeli tax authorities 514 0 0  
Increase (decrease) in other uncertain tax positions - net 171 0 0  
Tax benefits arising from reduced tax rates under benefit programs   14 15  
Mainly nondeductible items and prior year tax 16 0 35  
Impairments that did not have a corresponding tax effect, non-deductible interest and other items 463 372 941  
Adjustments to valuation allowances on deferred tax assets [1] (105) 0 0  
Worthless stock deduction [2]   0 (909)  
Increase (decrease) in other uncertain tax positions - net (1) 23 2  
Effective consolidated income taxes $ 676 $ (7) $ (643)  
[1] Mainly related to deduction of interest expenses in the United States.
[2] In 2022, one of Teva’s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva recognized on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with a related tax benefit of approximately $909 million.